Evidence map›Paper›PMID 34073468›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Synthesis of Multifunctional Nanoparticles for the Combination of Photodynamic Therapy and Immunotherapy.

Mei-Hwa Lee, James L Thomas, Jin-An Li, Jyun-Ren Chen, Tzong-Liu Wang, Hung-Yin Lin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Progress of Nanomaterials in Photodynamic Therapy Against Tumor.Frontiers in bioengineering and biotechnology · 2022
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Mei-Hwa LeeDepartment of Materials Science and Engineering, I-Shou University, Kaohsiung 84001, Taiwan.
James L ThomasDepartment of Physics and Astronomy, University of New Mexico, Albuquerque, NM 87131, USA.
Jin-An LiDepartment of Chemical and Materials Engineering, National University of Kaohsiung, Kaohsiung 81148, Taiwan.
Jyun-Ren ChenDepartment of Chemical and Materials Engineering, National University of Kaohsiung, Kaohsiung 81148, Taiwan.
Tzong-Liu WangDepartment of Chemical and Materials Engineering, National University of Kaohsiung, Kaohsiung 81148, Taiwan.ORCID 0000-0002-9144-850X
Hung-Yin LinDepartment of Chemical and Materials Engineering, National University of Kaohsiung, Kaohsiung 81148, Taiwan.
National University of Kaohsiung · TWI-Shou University · TWUniversity of New Mexico · US

Funding

Ministry of Science and Technology of ROC MOST 107-2923-M-390-001-MY3, MOST 108-2314-B-214-005-, MOST 108-2221-E-390-004-, MOST 109-2221-E-390-024- and MOST 109-2314-B-390-001-MY3
6 · The paper itself

Abstract

Programmed death-ligand 1 protein (PD-L1) has been posited to have a major role in suppressing the immune system during pregnancy, tissue allografts, autoimmune disease and other diseases, such as hepatitis. Photodynamic therapy uses light and a photosensitizer to generate singlet oxygen, which causes cell death (phototoxicity). In this work, photosensitizers (such as merocyanine) were immobilized on the surface of magnetic nanoparticles. One peptide sequence from PD-L1 was used as the template and imprinted onto poly(ethylene-

Indexed as

immunotherapymagnetic nanoparticlespeptide-imprinted polymerphotodynamic therapyprogrammed death-ligand 1 protein (PD-L1)

Identifiers

PMID34073468
PMCPMC8228393
OpenAlexW3164357821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.